Coating Process to Sustain Allogenic Bone Matrix

KEY INFORMATION

TECHNOLOGY CATEGORY

Medical Technology

TECHNOLOGY READINESS LEVEL (TRL) :

LOCATION :

Thailand

ID NUMBER :

TECHNOLOGY OVERVIEW

This innovative bone allograft technology employs advanced cold-sterilization and freeze-drying techniques, ensuring microorganism elimination while preserving natural bone properties. It retains essential bone-stimulating agents like BMP-2 and boasts a hydrophilic surface for superior cell and tissue adhesion. Through a unique coating process, it delays initial degradation, providing robust scaffolding for optimal bone regeneration. Its applications span dental implant treatments, contour maintenance, and enhancing human bone allografts by extending the crucial early healing phase.

TECHNOLOGY FEATURES & SPECIFICATIONS

Cold-Sterilization and Freeze-Drying for eliminating microorganisms
Maintenance of Bone-Stimulating Agents by BMP-2 for bone growth.
Hydrophilic Property, the bone allografts promote better cell and tissue adhesion.
The unique coating delays initial bone allograft degradation, ensuring strong support for later bone regeneration.

POTENTIAL APPLICATIONS

Bone substitutes are crucial in dental implant surgery for minimizing time and trauma.
Alloplastic or xenogeneic bone is homogenous but lacks active molecules, maintaining contour during healing.
Human bone allograft is rapidly absorbed, rich in regenerative gradients.
Sustain-release technology solves challenges by delivering bioactive molecules at the right time.
Xenogeneic and synthetic bone can utilize this technology for supplementing bioactive molecules.
Bone allograft offers benefits, including delayed turnover in the early period and maintaining space throughout healing.

MARKET TRENDS & OPPORTUNITIES

Bone grafting is the major adjunctive procedure of dental implant treatment. At least 50% of bone graft materials used in dental implant treatment is human bone allograft. Allogenic bone can carry bioactive molecules per se. Drug or bioactive molecules was valued at USD 1.97 Billion in 2021 and is projected to reach USD 5.56 Billion by 2030, growing at a CAGR of 12.49% from 2023 to 2030.

UNIQUE VALUE PROPOSITION

dult and geriatric dental patients need bioactive molecules for effective bone regeneration.
Premature release of bioactive molecules in the early wound healing phase is ineffective, leading to deficient stimulation during proliferation.
Conventional bone allograft’s rapid absorption can compromise the support function of dental implants.
Coating bone with bioactive gradients addresses these issues, ensuring sustained release and support throughout the entire healing period.